PLYMOUTH, Minn., July 21 /EMWNews/ -- ev3 Inc. (Nasdaq:

EVVV) today announced that effective July 18, 2008, Pascal E.R. Girin was

promoted to Executive Vice President of ev3 Inc. and President, Worldwide

Neurovascular and International. In this newly created position, Mr. Girin

will lead ev3's worldwide neurovascular business in addition to his current

responsibilities as President of International. The company also announced

that Matthew Jenusaitis has resigned his position as Senior Vice President

of ev3 Inc. and President, Neurovascular Division.



    Robert Palmisano, President and Chief Executive Officer of ev3 Inc.,

commented, "I'm delighted to announce Pascal's appointment to this new

position to lead our new global neurovascular organization and

international operations. Pascal's contributions as our President of

International have been exceptional, and his assumption of this role is a

natural consequence of the outstanding operational leadership that he has

provided since joining ev3. Pascal is a respected member of our operating

team and has been a major contributor to the company's growth and success,

including the expansion of our worldwide neurovascular business to the #2

overall revenue share position. I look forward to his continued future

contributions to ev3 in his new role."



    Girin joined ev3 in September 2003 as European General Manager. In July

2005, he was promoted to President of International and to Senior Vice

President of ev3 Inc. and President of International in August 2007. During

his tenure in these positions, ev3's international business expanded to

over 60 countries through a direct sales organization and distribution

network, and international net sales increased from $30.0 million in 2003

to $107.0 million in 2007. Prior to joining ev3, Mr. Girin served in

various capacities at Baxter Healthcare Corporation's BioScience Division

in Europe, including Vice President. Mr. Girin received an engineering

education at the French Ecole des Mines.

    About ev3 Inc.



    Since its founding in 2000, ev3 has been dedicated to developing

innovative, breakthrough and clinically proven technologies and solutions

for the treatment of lower extremity vascular and neurovascular diseases.

ev3's products are used by endovascular specialists to treat a wide range

of peripheral vascular and neurovascular diseases and disorders. The

company offers a comprehensive portfolio of treatment options, including

the primary interventional technologies used today -- peripheral

angioplasty balloons, stents, plaque excision systems, embolic protection

devices, liquid embolics, embolization coils, thrombectomy catheters and

occlusion balloons. More information about the company and its products can

be found at http://www.ev3.net.



    ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S.

and other countries.